Abstract
Introduction: A biomarker is a measurable indicator of normal biologic processes, pathogenic processes or pharmacological responses. The identification of a useful biomarker is challenging, with several hurdles to overcome before clinical adoption. This review gives a general overview of a range of biomarkers associated with inflammatory bowel disease or colorectal cancer along the gastrointestinal tract.
Areas covered: These markers include those that are already clinically accepted, such as inflammatory markers such as faecal calprotectin, S100A12 (Calgranulin C), Fatty Acid Binding Proteins (FABP), malignancy markers such as Faecal Occult Blood, Mucins, Stool DNA, Faecal microRNA (miRNA), other markers such as Faecal Elastase, Faecal alpha-1-antitrypsin, Alpha2-macroglobulin and possible future markers such as microbiota, volatile organic compounds and pH.
Expert commentary: There are currently a few biomarkers that have been sufficiently validated for routine clinical use at present such as FC. However, many of these biomarkers continue to be limited in sensitivity and specificity for various GI diseases. Emerging biomarkers have the potential to improve diagnosis and monitoring but further study is required to determine efficacy and validate clinical utility
Areas covered: These markers include those that are already clinically accepted, such as inflammatory markers such as faecal calprotectin, S100A12 (Calgranulin C), Fatty Acid Binding Proteins (FABP), malignancy markers such as Faecal Occult Blood, Mucins, Stool DNA, Faecal microRNA (miRNA), other markers such as Faecal Elastase, Faecal alpha-1-antitrypsin, Alpha2-macroglobulin and possible future markers such as microbiota, volatile organic compounds and pH.
Expert commentary: There are currently a few biomarkers that have been sufficiently validated for routine clinical use at present such as FC. However, many of these biomarkers continue to be limited in sensitivity and specificity for various GI diseases. Emerging biomarkers have the potential to improve diagnosis and monitoring but further study is required to determine efficacy and validate clinical utility
| Original language | English |
|---|---|
| Pages (from-to) | 1119-1134 |
| Number of pages | 16 |
| Journal | Expert Review of Gastroenterology and Hepatology |
| Volume | 11 |
| Issue number | 12 |
| Early online date | 14 Sept 2017 |
| DOIs | |
| Publication status | Published - 2 Dec 2017 |
Keywords
- biomarker
- gastrointestinal disease, faecal calprotectin, lactoferrin, phagocyte derived protein,
- volatilome
- microbiome
- faecal occult blood testing
- fatty acid binding proteins
- mucins
Access to Document
- Download pdf
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology on 29 Aug 2017, available online: http://dx.doi.org/10.1080/17474124.2017.1373017